The cases of double sleeve uniportal thoracoscopic lobectomy in Shanghai Pulmonary Hospital were retrospectively analyzed and the key points of operational technique were summarized, to further discuss and explore the operation effects and application values.

A total of 47 patients who underwent double sleeve uniportal thoracoscopic lobectomy in Shanghai Pulmonary Hospital from June 2015 to January 2021 were consecutively enrolled. Patients were followed up remotely by telephone every 6 months post-operation. The operation duration, intraoperative bleeding, drainage volume on the first day after operation, postoperative hospital stay, complications and 1- and 2-year survival rates were recorded and analyzed.

A total of 41 males and 6 females were enrolled, with an age of (60.5±8.0) years. 41 (87.2%) cases received left upper lobe double sleeves lobectomy, 3 (6.4%) cases received right upper lobe double sleeves lobectomy and 3 (6.4%) cases received right and middle double sleeves bilobectomy. The main pathological type was squamous cell carcinoma (30, 63.8%) . There were 9 (19.1%) , 17 (36.2%) and 21 (44.7%) of patients who had TNM stages of stage I, II and III, respectively. The mean operation duration was (2.7 ± 0.8) h, the mean intraoperative blood loss was (168.1±160.0) mL, and the mean postoperative hospital stay was (5.9±2.9) days. There was no case conversing to thoracotomy. The median follow-up time was 27 months. The 1-year overall survival rate was 87.9% and the 2-year overall survival rate was 68.7%.

Double sleeve uniportal thoracoscopic lobectomy can be used to completely remove tumors and preserve lung function to the greatest extent with reduced surgical traumas. This operation is technique-demanding, which is feasible and safe when carried out in thoracic centers with endoscopy proficiency.